HIV

Infectious Diseases
67
Pipeline Programs
22
Companies
50
Clinical Trials
3 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
1
14
5
9
30
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1280%
Cell Therapy
17%
RNA Therapeutic
17%
Vaccine
17%
+ 106 programs with unclassified modality

On Market (5)

Approved therapies currently available

U
PITAVASTATIN CALCIUMApproved
pitavastatin
Unknown Company
oral2016
Bristol Myers Squibb
REYATAZApproved
atazanavir
Bristol Myers Squibb
oral2003
GS
VEMLIDYApproved
tenofovir alafenamide
Gilead Sciences
oral2016
Bausch Health
XIFAXANApproved
rifaximin
Bausch Health
Rifamycin Antibacterial [EPC]oral2004
U
ZIDOVUDINEApproved
zidovudine
Unknown Company
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]oral2006

Competitive Landscape

21 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
57 programs
2
4
3
9
17
Descovy 200Mg 25Mg TabletPhase 41 trial
Descovy 200Mg 25Mg TabletPhase 4
Digital Health Feedback SystemPhase 41 trial
EvipleraPhase 42 trials
EvipleraPhase 4
+52 more programs
Active Trials
NCT04240691Completed52Est. Apr 2024
NCT01790633Completed327Est. Oct 2013
NCT04193787Completed100Est. Sep 2024
+38 more trials
M&
Merck & Co.RAHWAY, NJ
13 programs
3
2
DELSTRIGO 100Mg-300Mg-300Mg TabletPhase 41 trial
Tenofovir/emtricitabinePhase 41 trial
AtazanavirPhase 2Small Molecule1 trial
Peg-IFN-α2bPhase 21 trial
Vicriviroc maleatePhase 21 trial
+8 more programs
Active Trials
NCT02597790Completed87Est. Jan 2020
NCT03324633Completed1,850Est. Dec 2022
NCT02025322Unknown36Est. Sep 2015
+10 more trials
Bristol Myers Squibb
7 programs
1
1
2
REYATAZ(Atazanavir)Phase 4Small Molecule1 trial
atazanavir/raltegravirPhase 4Small Molecule
SalsalatePhase 21 trial
Microgynon 30®Phase 11 trial
Comparative Tolerability of Protease InhibitorsN/A1 trial
+2 more programs
Active Trials
NCT01450618Completed26,000Est. Oct 2012
NCT02628340Completed20Est. Jul 2016
NCT02697851Terminated13Est. Oct 2017
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
Nevirapine, FTC, and TenofovirPhase 4Small Molecule1 trial
lopinavir/ritonavir; nevirapine; Zidovudine; LamivudinePhase 4
Active Trials
NCT00344461Completed54Est. Jul 2008
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
RifaximinPhase 41 trial
Active Trials
NCT01654939WithdrawnEst. Sep 2015
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
RifaximinPhase 4
CytoDyn
CytoDynVANCOUVER, WA
6 programs
3
2
PRO 140Phase 2/31 trial
PRO 140Phase 2/31 trial
PRO 140Phase 21 trial
PRO 140Phase 21 trial
PRO 140 350mg weekly subcutaneousPhase 21 trial
+1 more programs
Active Trials
NCT02759042No Longer Available
NCT01272258Withdrawn0Est. Feb 2017
NCT02175680Completed43Est. Feb 2015
+3 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
14 programs
4
1
1
Peg-IFN-α2bPhase 2
PGDM1400LSPhase 1/21 trial
FP conjugate vaccinePhase 1Vaccine1 trial
RitonavirPhase 1Small Molecule1 trial
TDF Intravaginal RingPhase 11 trial
+9 more programs
Active Trials
NCT00433628Completed
NCT01204814CompletedEst. Jul 2011
NCT03734393Active Not RecruitingEst. Feb 2026
+10 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
1
PF-00232798Phase 21 trial
maravirocN/A1 trial
non-interventional trialN/A1 trial
Active Trials
NCT01329783Completed1,181Est. Mar 2011
NCT01339403Completed282,368Est. Oct 2013
NCT00495677Completed43Est. Sep 2008
Abbott
AbbottABBOTT PARK, IL
1 program
1
RifabutinPhase 21 trial
Active Trials
NCT01663168Unknown140Est. Jan 2014
Moderna
ModernaCAMBRIDGE, MA
1 program
1
Core-g28v2 60mer mRNA VaccinePhase 1RNA Therapeutic1 trial
Active Trials
NCT05001373Active Not Recruiting56Est. Jul 2024
Alliance Pharmaceuticals
5 programs
Adherence and retention packageN/A1 trial
ControlN/A5 trials
Systems Analysis and Improvement ApproachN/A1 trial
TruvadaN/A1 trial
pMTCT systems analysis and improvementN/A1 trial
Active Trials
NCT02371265Completed761Est. Aug 2015
NCT07290335Recruiting100,000Est. Apr 2027
NCT06821074Recruiting1,000Est. Feb 2027
+6 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
MopatiN/A1 trial
Understanding Reproductive Health for LadeezN/A1 trial
Active Trials
NCT04796610CompletedEst. Aug 2022
NCT02733692CompletedEst. Jun 2016
Design Therapeutics
1 program
COMMIT mHealth applicationN/A1 trial
Active Trials
NCT04462679UnknownEst. Jul 2021
Roche
RocheSTAVANGER NORWAY, Norway
1 program
ELISAN/A
Lead Pharma
Lead PharmaNetherlands - Oss
1 program
Minimum package of interventions to improve ART adherenceN/A1 trial
Active Trials
NCT02536768CompletedEst. Apr 2018
Trace Biosciences
Trace BiosciencesOR - Beaverton
1 program
Multivitamin AN/A
Element Biosciences
Element BiosciencesCA - San Diego
1 program
Multivitamin AN/A1 trial
Active Trials
NCT02552602UnknownEst. Feb 2016
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
Organizational PartnershipsN/A1 trial
Active Trials
NCT06171919RecruitingEst. Aug 2026
Plus Therapeutics
1 program
TRI-MOM interventionN/A1 trial
Active Trials
NCT05951751RecruitingEst. May 2025
Novartis
NovartisBASEL, Switzerland
1 program
tobacco smoking substitution productsN/A1 trial
Active Trials
NCT06789692Recruiting972Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Gilead SciencesLenacapavir long-acting
Gilead SciencesLenacapavir long-acting
Merck & Co.DELSTRIGO 100Mg-300Mg-300Mg Tablet
Gilead SciencesDescovy 200Mg 25Mg Tablet
Gilead SciencesFTC/TAF
Gilead SciencesTruvada
Gilead SciencesDigital Health Feedback System
Gilead SciencesEviplera
Gilead SciencesEviplera
Gilead SciencesStribild
T-TherapeuticsRifaximin
Gilead SciencesTenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Merck & Co.Tenofovir/emtricitabine
Bristol Myers SquibbAtazanavir
Gilead SciencesRaltegravir, tenofovir/emtricitabine

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 16,502 patients across 50 trials

A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients

Phase 4Unknown
NCT07218211Gilead SciencesLenacapavir long-acting

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

Start: Jan 2026Est. completion: Jan 2028100 patients
Phase 4Recruiting
NCT07210125Gilead SciencesLenacapavir long-acting

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

Start: Sep 2025Est. completion: Jun 202775 patients
Phase 4Recruiting
NCT05289986Merck & Co.DELSTRIGO 100Mg-300Mg-300Mg Tablet

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

Start: Nov 2023Est. completion: Nov 202418 patients
Phase 4Terminated
NCT04782180Gilead SciencesDescovy 200Mg 25Mg Tablet

PrEP at a Syringe Services Program

Start: Feb 2022Est. completion: Nov 202490 patients
Phase 4Completed

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Start: Nov 2017Est. completion: May 201837 patients
Phase 4Completed

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Start: Oct 2016Est. completion: Oct 2018451 patients
Phase 4Completed
NCT02800655Gilead SciencesDigital Health Feedback System

Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

Start: Jun 2016Est. completion: Dec 2023100 patients
Phase 4Unknown

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

Start: Nov 2015Est. completion: May 201740 patients
Phase 4Completed

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

Start: Feb 2015Est. completion: Jun 201758 patients
Phase 4Completed

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

Start: Feb 2015Est. completion: Jan 201621 patients
Phase 4Completed

Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

Start: Oct 2012Est. completion: Sep 2015
Phase 4Withdrawn
NCT01602822Gilead SciencesTenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Start: Feb 2012Est. completion: May 201211 patients
Phase 4Terminated
NCT01270802Merck & Co.Tenofovir/emtricitabine

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Start: Apr 2011Est. completion: Apr 201330 patients
Phase 4Completed

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Start: Feb 2011Est. completion: Jun 201125 patients
Phase 4Completed
NCT01025427Gilead SciencesRaltegravir, tenofovir/emtricitabine

HIV Persistence and Viral Reservoirs

Start: Dec 2009Est. completion: Oct 201316 patients
Phase 4Completed

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Start: Aug 2006Est. completion: Jul 200917 patients
Phase 4Completed
NCT00344461Boehringer IngelheimNevirapine, FTC, and Tenofovir

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Start: Mar 2004Est. completion: Jul 200854 patients
Phase 4Completed
NCT04937881Gilead SciencesTenofovir alafenamide

PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

Start: Jun 2022Est. completion: Sep 202339 patients
Phase 3Completed

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Start: Mar 2015Est. completion: Aug 20237,769 patients
Phase 3Completed

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Start: Feb 2014Est. completion: Oct 201679 patients
Phase 3Completed

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Start: Oct 2013Est. completion: Jul 201755 patients
Phase 3Completed

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Start: Mar 2013Est. completion: Jul 2018252 patients
Phase 3Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Start: Mar 2013Est. completion: Apr 20201,443 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Start: Dec 2012Est. completion: Sep 2017872 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Start: Mar 2010Est. completion: Sep 2014707 patients
Phase 3Completed

Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis

Start: Jan 2008Est. completion: Feb 20141,931 patients
Phase 3Completed

Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients

Start: Oct 2006Est. completion: Jul 2009300 patients
Phase 3Unknown

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Start: Dec 2016Est. completion: Dec 2020562 patients
Phase 2/3Completed

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

Start: Oct 2015Est. completion: Jul 201852 patients
Phase 2/3Completed

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

Start: Dec 2014Est. completion: Oct 201760 patients
Phase 2/3Completed
NCT02104700Gilead SciencesRilpivirine/Emtricitabine/Tenofovir

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

Start: Apr 2014Est. completion: Jul 2016150 patients
Phase 2/3Completed

Reducing Proviral HIV DNA With Interferon-a

Start: Feb 2015Est. completion: Jul 201854 patients
Phase 2Unknown
NCT02355184CytoDynPRO 140 350mg weekly subcutaneous

An Extension of Protocol PRO 140_CD01 Study

Start: Nov 2014Est. completion: Jul 202220 patients
Phase 2Terminated

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Start: Apr 2014Est. completion: Feb 201543 patients
Phase 2Completed

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

Start: Dec 2013Est. completion: Feb 20170
Phase 2Withdrawn

EARNEST Rifabutin Pharmacokinetics (PK) Substudy

Start: Dec 2011Est. completion: Jan 2014140 patients
Phase 2Unknown

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Start: Jan 2009Est. completion: Jul 200940 patients
Phase 2Completed

Phase IIB Pilot of Atazanavir + Raltegravir

Start: Nov 2008Est. completion: May 2010167 patients
Phase 2Terminated

A Phase 2 Study Of PF-00232798 In HIV Positive Patients

Start: Jun 2007Est. completion: Sep 200843 patients
Phase 2Completed
NCT00298350Gilead SciencesGS-9137 - A Novel HIV-1 Integrase Inhibitor

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Start: Feb 2006Est. completion: Jul 2007278 patients
Phase 2Completed
NCT00686829Merck & Co.Vicriviroc maleate

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

Start: Jun 2005Est. completion: Oct 201079 patients
Phase 2Completed
NCT00270556Gilead Sciencestenofovir disoproxil fumarate

Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.

Start: Jan 2003Est. completion: Oct 2004100 patients
Phase 2Completed

The Tatelo Plus Study

Start: Nov 2024Est. completion: Apr 2028
Phase 1/2Recruiting

The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients

20 patients
Phase 1Completed

Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS.

Start: Oct 2022Est. completion: Nov 202316 patients
Phase 1Completed

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Start: Aug 2022Est. completion: Jan 2024
Phase 1Completed
NCT05001373ModernaCore-g28v2 60mer mRNA Vaccine

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Start: Nov 2021Est. completion: Jul 202456 patients
Phase 1Active Not Recruiting

Pharmacokinetic Effect of Evotaz/Microgynon Co-administration

Start: Jul 2016Est. completion: Oct 201713 patients
Phase 1Terminated

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Start: Apr 2015Est. completion: Jul 201519 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 16,502 patients
22 companies competing in this space